The FDA granted Priority Review of the supplemental Biologics License Application (sBLA) for epcoritamab-bysp. This subcutaneously administered T-cell engaging bispecific…
Ad Blocker Enabled!
Ad Blocker Enabled!
Our website is made possible by online advertisements. Please support us by disabling your Ad Blocker.
